NYSE:BLCO Bausch + Lomb Q3 2026 Earnings Date & Estimates $16.69 +0.65 (+4.04%) Closing price 10/15/2026 03:59 PM EasternExtended Trading$16.69 +0.00 (+0.01%) As of 05:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Bausch + Lomb is scheduled to report Q3 2026 earnings on Wednesday, October 28, 2026, before market opens. The conference call is scheduled for 8:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateOctober 28, 2026TimeBefore Market OpensConference Call8:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Bausch + Lomb in Q3 2026Bausch + Lomb is expected to post earnings of $0.2147 per share on revenue of $1.37 billion. In the same quarter a year earlier Bausch + Lomb reported $0.18 per share on revenue of $1.28 billion. Bausch + Lomb last reported on July 29, 2026, posting $0.15 per share and missing the $0.16 consensus estimate. Bausch + Lomb has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS$0.2147Expected Revenue$1.37 billionPrior-Year EPS$0.18Prior-Year Revenue$1.28 billionExpected EPS Growth+19.3%Expected Revenue Growth+7.1%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$0.15 (Missed by -$0.01)Last Quarter Revenue$1.39 billionEPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Bausch + Lomb Q3 2026 Earnings FAQ When does Bausch + Lomb report Q3 2026 earnings? Bausch + Lomb (NYSE:BLCO) has confirmed it will report Q3 2026 earnings on Wednesday, October 28, 2026, before market opens. What time is Bausch + Lomb's Q3 2026 earnings call? Bausch + Lomb's Q3 2026 earnings conference call is scheduled for Wednesday, October 28, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Bausch + Lomb? Analysts expect Bausch + Lomb to post earnings of $0.2147 per share for Q3 2026. How much revenue is Bausch + Lomb expected to report? The consensus revenue estimate for Bausch + Lomb is $1.37 billion for Q3 2026. Bausch + Lomb Earnings HeadlinesBausch + Lomb Corporation Announces Cessation of Brent Saunders as Director, Effective October 12, 2026October 13 at 3:06 PM | marketscreener.comMBausch + Lomb Stock Rises 9% As Interim CEO Takes Over And 2026 Guidance Is RaisedOctober 12, 2026 | rttnews.comStop picking AI winners. Start collecting every ThursdayOne fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution rate. Instead of guessing which AI stock wins, this fund delivers income every single Thursday, up to $1,051 a month. Chief Income Strategist Tim Plaehn breaks down what's inside the fund and how the weekly payouts work.October 16 at 1:00 AM | Investors Alley (Ad)Bausch + Lomb CEO Saunders departs, Chairman Appio named interim chiefOctober 12, 2026 | reuters.comBausch + Lomb Names Thomas Appio Interim CEO; Expects to Raise 2026 GuidanceOctober 12, 2026 | finance.yahoo.comBausch + Lomb (NYSE:BLCO) Stock Falls 5.8% - Should You Sell?October 12, 2026 | americanbankingnews.comSee More Bausch + Lomb Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bausch + Lomb? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bausch + Lomb and other key companies, straight to your email. Email Address About Bausch + LombBausch + Lomb (NYSE:BLCO) (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, pharmaceuticals and surgical applications. Its portfolio is intended to address a broad range of eye conditions and support patients, eye-care professionals and surgical specialists. The company’s vision-care products include contact lenses and contact-lens-care solutions, while its pharmaceutical portfolio includes prescription and over-the-counter treatments for conditions affecting the eyes. Bausch + Lomb also supplies ophthalmic surgical products, equipment and technologies used in procedures such as cataract and refractive surgery. Founded in 1853 in Rochester, New York, Bausch + Lomb operates internationally and sells its products in numerous markets around the world. The company was formerly part of Bausch Health Companies and became an independent publicly traded company in 2022. Its chief executive officer is Brent Saunders.View Bausch + Lomb ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
